DNTH · Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

7 Times Square, New York, NY, 10036, United States
Biotechnology
Healthcare

Market Cap

4.729B

52 Wk Range

$35.84 - $117.88

Previous Close

$83.98

Open

$84.33

Volume

896,829

Day Range

$83.25 - $87.12

Enterprise Value

4.062B

Cash

837.8M

Avg Qtr Burn

-50.33M

Insider Ownership

0.12%

Institutional Own.

N/A

Qtr Updated

Sep 30th 2026